论文部分内容阅读
自马利兰等应用于慢性粒细胞白血病(CML)化疗后,缓解率虽然很高,但对生存期的延长并不十分明显,中位数生存期一直保持在3年左右,长期存活病例并不多。为进一步探讨CML治疗效果,延长生存期,我们自1984年开始对CML诱导缓解后的患者,予以强化治疗,现将结果报告如下。 1 一般资料 1984年1月至1997年12月,我院共收治CML患者42例,男25例,女17例,中数年龄43(20～71)岁。全部病例均经临床、血象及骨髓象等检查确诊。诊断及分期标准根据第二届全国血液病治疗讨论会制定的标准。其中慢性期32例,加速期10例。
Since Maryland et al. applied to chronic myelocytic leukemia (CML) chemotherapy, although the remission rate was high, the survival period was not prolonged. The median survival period remained at 3 years, and there were not many cases of long-term survival. . In order to further explore the therapeutic effect of CML and prolong the survival period, we have intensively treated CML-induced remission after 1984 and report the results as follows. 1 General Information From January 1984 to December 1997, 42 cases of CML patients were treated in our hospital. There were 25 males and 17 females. The median age was 43 (20-71) years old. All cases were confirmed by clinical, blood and bone marrow examinations. The diagnostic and staging criteria are based on the standards set by the Second National Hematology Treatment Symposium. Among them, 32 patients were in chronic phase and 10 patients in accelerated phase.